Wedbush analyst Liana Moussatos reiterated a Buy rating on Zafgen (ZFGN) today and set a price target of $6. The company’s shares opened today at $1.36, close to its 52-week low of $1.31.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -8.6% and a 32.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zafgen with a $6.75 average price target, which is a 396.3% upside from current levels. In a report issued on May 30, Piper Jaffray also maintained a Buy rating on the stock with a $5 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.36 and a one-year low of $1.31. Currently, Zafgen has an average volume of 310.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases.
